The objective of this study was to conduct a survey of the opinions and practices of gastroenterologists in the United Kingdom concerning the impact of Helicobacter pylori infection on the management of upper gastrointestinal diseases. A postal questionnaire was sent to all medically qualified members of the British Society of Gastroenterology working in the UK. Replies were received from 670 of 1037 eligible BSG members (65%). Of these, 73% thought that Hpylorn was a cause of duodenal ulcer and 84% thought that eradication of H pylori decreased ulcer recurrence in comparison with acid suppression. While 80% used anti-H pylon therapy for a chronic relapsing duodenal ulcer, only 25% used such therapy for an ulcer at first presentation and 17% never used anti-Hpylori therapy for patients with duodenal ulcer. Although 75% of respondents did not agree that Hpylori was a cause of non-ulcer dyspepsia, 69% used anti-H pyloni therapy to treat a patient with this condition. At the time of the survey, 69% of those who used anti-H pylori therapy adopted some variant of standard triple therapy. Only 7% routinely tested for bacterial sensitivity to antibiotics and only 22% assessed their patients for eradication after treatment. There was a lack ofconsensus about whether H pylori was a cause of gastric ulcer or gastric cancer with only 47% and 17% respectively believing in these associations. In conclusion, at the time of the survey, the use of anti-H pylori therapy had been accepted by a majority of specialist UK gastroenterologists in the management of upper gastrointestinal disease. There was, however, a substantial degree of uncertainty and divergence about which patients should be treated. (Gut 1995; 37: 314-318) 
The characterisation of the gastric bacterium Helicobacter pylori in 19831 and subsequent evidence to show that infection is a major cause of gastritis and peptic ulcer2A4 has brought about profound changes in gastroenterological practice. Eradication of H pylori has become a practical therapeutic option and an important alternative to acid suppression in the management of patients with peptic ulcer disease. [4] [5] [6] As with many new medical developments,7 H pylori eradication therapy has been adopted in a haphazard fashion with enthusiasts and sceptics being respectively more or less convinced about the need to change their practice. This study was designed to gauge the state of specialist opinion and practice concerning the role of H pylori in gastroduodenal diseases within the UK in the first half of 1993.
Methods
Medically qualified members of the British Society of Gastroenterology (BSG), currently working in the UK, were sent a postal questionnaire in February 1993 (copies available from Dr Milne). Reminders were sent to all non-respondents after four and eight weeks. The questionnaire had five sections. The first asked about the respondents' age, specialty, place of work, and amount of upper gastrointestinal work carried out in the previous year. The second section asked about attitudes to the aetiology and treatment of upper gastrointestinal disease (with a particular emphasis on the role of H pylori and the importance of its eradication), using statements to which respondents were asked to indicate their attitude on a five point scale ranging from 'strongly agree' to 'strongly disagree'. The third section asked respondents directly involved in the clinical management of patients how they would treat six cases (described in brief vignettes, see Appendix). These represented patients with: a duodenal ulcer at first presentation; at first recurrence; and after persistent recurrence; a gastric ulcer; a gastric ulcer associated with nonsteroidal anti-inflammatory drug (NSAID) use; and non-ulcer dyspepsia. The fourth section of the questionnaire asked those respondents who offered H pylori eradication therapy about their method of diagnosis, treatment regimens, and follow up procedures. The final section, only for consultant physicians and surgeons, asked about attitudes to clinical trials and treatment protocols for duodenal ulcer patients.
The data were analysed using SPSS for Windows (version 6.0). Most results are presented as simple frequency distributions. We used the standard deviation of attitude scores as a means of consensus (the higher the standard deviation, the less the consensus). Non-ulcer dyspepsia 90 (16) 21 (4) 385 (69) Eighty seven respondents (13%) reported having had their own Hpylori status tested and, of these, 37 (43°/O) tested positive and 50 (57°/O) were negative. Ten respondents had their infections successfully treated. Table I shows the responses to the 15 attitudinal questions, presented in order of increasing standard deviation. Five of the questions were concerned with beliefs about the aetiological role of H pylori. There was strong consensus and agreement that H pylori was a cause of antral gastritis (87% agreeing with statement 1) and duodenal ulcer (73% agreeing with statement 9). In contrast, only 7% and 25% of respondents agreed that it was a cause of gastric cancer (statement 2) and non-ulcer dyspepsia (statement 11) respectively. Many respondents were neutral about the role of Hpylori in gastric cancer (58% neutral), gastric ulcer (4 1%), and non-ulcer dyspepsia (40%/o) and, for all these diseases, a substantial minority of respondents disagreed that the H pylorn had a causative role (25%, 13%, and 35% respectively).
The 10 remaining attitude questions were concerned with the treatment of H pylori. It was generally accepted that eradication of H pylori decreased recurrence rates of duodenal ulcer (84% agreeing with statement 3) but that, in comparison with acid suppression, the therapy caused more side effects (statement 7) and decreased patient compliance (statement 8). The lack of compliance was not thought to be sufficiently great to justify withholding H pylorn therapy from routine use (statement 10), nor was there a major concern about the risk of pseudo membranous colitis from antibiotic therapy (statement 4).
Although 18% of respondents thought that the efficacy of anti-H pylori therapy for the treatment of duodenal ulcer was still unproved (statement 13), 55% thought that such therapy would become standard treatment within five years (statement 12). Fifty nine per cent of respondents thought that anti-H pylori therapy should only be offered to patients with non-ulcer dyspepsia as part of a clinical trial (statement 15).
A total of 561 respondents (71% physicians, 25% surgeons, and 4% others) answered the questions about treatment of the six patients described in the vignettes and the responses are summarised in Table II A majority of respondents stated that they would treat both of the patients with gastric ulcer (patients four and five) with H2 antagonists, 300 (54%) treating patient four and 287 (5 1%) treating patient six in this way. For the uncomplicated ulcer, anti-Hpylori therapy was the next most popular therapy, mentioned by 211 respondents (38%) followed by proton pump inhibitors, mentioned by 129 (23%).
For the NSAID associated ulcer, the use of these latter strategies was reversed with 220 (39%) favouring proton pump inhibitors and 99 (18%) favouring anti-Hpylorn therapy.
For patient six, with non-ulcer dyspepsia, 385 respondents (69%) said they would use anti-Hpylorn therapy compared with 90 (16%) using H2 antagonists and 21 (4%) using proton pump inhibitors.
Of the 519 respondents who treated Hpylori, 23 (4%) were not using a routine test to establish the presence of infection. The majority of the remaining respondents used either histological examination (74%) or a biopsy urease test (58%) or both, to establish the diagnosis. Other tests used, not necessarily exclusively, were culture (14%), urea breath test (6%) or serology (3%). Only 35 (7%) respondents tested for antimicrobial susceptibility.
Three hundred and fifty eight respondents (69%) used some form of triple therapy, under which heading were included all regimens that included bismuth, a nitroimidazole, and a second antibiotic, most commonly amoxycillin or tetracycline. There was considerable variation in the triple therapy reported, and although 305 of 358 (85%) followed the Sidney recommendations6 as far as drug type is concerned, there was a wide range of doses, frequencies, and treatment durations. The second commonest treatment option was a proton pump inhibitor/antibiotic combination, suggested by 65 (13%) respondents.
Asked if they routinely monitored patients for eradication, 112 of 516 (22%) said they did, although seven did so at less than four weeks, which is the time interval regarded as necessary to elapse for valid assessment of eradication. Sixty six of 112 (59%) used tests requiring further endoscopy, 21 (19%) used serology or the urea breath test, or both, and 14 (13%) used a mixture of both. More of the enthusiasts were likely to test for antimicrobial sensitivity than the sceptics (10% compared with 6%) and more were likely to monitor their patients for bacterial eradication four weeks or more after treatment (24% compared with 12%), but these differences were not statistically significant.
Of the 501 consultant physicians and surgeons, 394 (79%/o) stated that large randomised clinical trials were needed to resolve existing uncertainties about the role of H pylori in duodenal ulcer. In contrast only 55 (11%) were entering patients into such trials although 367 (73%) said they would consider joining them.
Thirty five per cent of respondents reported having a duodenal ulcer treatment protocol in their department and, of these, 97% stated it was adhered to often, or nearly always. Discussion This is the first major survey of UK gastroenterologists on the impact of H pylori infection and associated disease. The response rate of 65%, although similar to that in other surveys of the BSG membership,8 is sufficiently low to raise concerns that the respondents might represent a biased sample of members. We believe, however, that our respondents included a high proportion of BSG members directly involved in patient management. It He is a non-smoker and only drinks socially: endoscopy reveals a 4 mm anterior DU. Patient 2 A 54 year old non-smoking housewife, with a DU diagnosed by OGD 10 years previously (treated only with 6 months H2 antagonist), was well until 3 months ago when recurrent epigastric pain prompted GP referral: OGD showed duodenitis and multiple duodenal erosions. parisons with other clinical groups, notably general practitioners, and with gastroenterologists in other countries and, at future time points, in the UK. We hope to be able to monitor changes in attitude and practice both over time and within different sections of the medical profession.
